Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A modular framework for the development of targeted Covid-19 blood transcript profiling panels.
Rinchai D, Syed Ahamed Kabeer B, Toufiq M, Tatari-Calderone Z, Deola S, Brummaier T, Garand M, Branco R, Baldwin N, Alfaki M, Altman MC, Ballestrero A, Bassetti M, Zoppoli G, De Maria A, Tang B, Bedognetti D, Chaussabel D. Rinchai D, et al. Among authors: bedognetti d. J Transl Med. 2020 Jul 31;18(1):291. doi: 10.1186/s12967-020-02456-z. J Transl Med. 2020. PMID: 32736569 Free PMC article.
Author Correction: Positive regulation of oxidative phosphorylation by nuclear myosin 1 protects cells from metabolic reprogramming and tumorigenesis in mice.
Venit T, Sapkota O, Abdrabou WS, Loganathan P, Pasricha R, Mahmood SR, El Said NH, Sherif S, Thomas S, Abdelrazig S, Amin S, Bedognetti D, Idaghdour Y, Magzoub M, Percipalle P. Venit T, et al. Among authors: bedognetti d. Nat Commun. 2023 Nov 30;14(1):7878. doi: 10.1038/s41467-023-43936-2. Nat Commun. 2023. PMID: 38036530 Free PMC article. No abstract available.
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M. Noviello TMR, et al. Among authors: bedognetti d. Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4. Nat Commun. 2023. PMID: 37739939 Free PMC article. Clinical Trial.
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
Zoppoli G, Cea M, Soncini D, Fruscione F, Rudner J, Moran E, Caffa I, Bedognetti D, Motta G, Ghio R, Ferrando F, Ballestrero A, Parodi S, Belka C, Patrone F, Bruzzone S, Nencioni A. Zoppoli G, et al. Among authors: bedognetti d. Exp Hematol. 2010 Nov;38(11):979-88. doi: 10.1016/j.exphem.2010.07.013. Epub 2010 Aug 7. Exp Hematol. 2010. PMID: 20696207 Free article.
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.
Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH. Ascierto ML, et al. Among authors: bedognetti d. J Transl Med. 2013 Jun 12;11:145. doi: 10.1186/1479-5876-11-145. J Transl Med. 2013. PMID: 23758773 Free PMC article.
Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus.
Ascierto ML, Bozzano F, Bedognetti D, Marras F, Schechterly C, Matsuura K, Picciotto A, Marenco S, Zhao Y, DeGiorgi V, Sommariva M, Moretta L, Wang E, Alter HJ, Marincola FM, De Maria A. Ascierto ML, et al. Among authors: bedognetti d. J Transl Med. 2015 Mar 1;13:77. doi: 10.1186/s12967-015-0428-x. J Transl Med. 2015. PMID: 25849716 Free PMC article.
135 results